FINWIRES · TerminalLIVE
FINWIRES

TYO:2587

3 stories mentioning TYO:2587Updated 38d ago

Every FINWIRES story that references TYO:2587, newest first.

What's the latest news on TYO:2587?

Asia

Suntory Beverage & Food's Attributable Profit Edges Up 2% in H1

Suntory Beverage & Food (TYO:2587) posted a 2.3% year-over-year increase in attributable profit for the fiscal first half to 42.1 billion yen from 41.1 billion yen.Basic EPS was 136.17 yen, compared with 133.13 yen a year earlier, according to a Tokyo bourse filing on Thursday.Revenue rose 12% to 899.9 billion yen from 806.4 billion yen for the six months ended June 30.The beverage and food company declared an interim dividend of 60 yen per share, payable from Sept. 3.For the fiscal year ending Dec. 31, the company expects attributable profit of 89.0 billion yen, basic EPS of 288.03 yen and revenue of 1.826 trillion yen.The company plans to pay year-end dividends of 60 yen per per share for the current year, which is unchanged from the year-ago period.Shares of the company rose nearly 3% in recent trade.

TYO:2587
Asia

Suntory PepsiCo Opens Sixth Vietnam Plant

Suntory PepsiCo Vietnam (SPVB) opened its sixth manufacturing facility in Vietnam, a $300 million plant in Tay Ninh province near Ho Chi Minh City, the company said in a LinkedIn post.The facility incorporates integrated automation, digital manufacturing systems and SPVB's first fully automated warehouse in Vietnam and the region.The plant has an annual production capacity of 1.24 billion liters and will manufacture seven beverage brands, including Pepsi, Aquafina and 7Up, according to a Monday Nikkei Asia report.SPVB is a joint venture between Suntory Beverage & Food (TYO:2587) and PepsiCo.Shares of Suntory Beverage rose nearly 1% in recent trade.

TYO:2587
Asia

Market Chatter: Suntory Eyes Daiichi Sankyo Healthcare in 200 Billion Yen Deal

Suntory Beverage & Food (TYO:2587) is set to acquire Daiichi Sankyo's (TYO:4568) over-the-counter drug unit for about 200 billion yen as the beverage maker expands its health-related business, Nikkei reported WednesdayThe deal would see Daiichi Sankyo divest its healthcare arm, which produces products such as painkiller Loxonin, stomach medicine Gaster 10 and cold remedy Lulu, according to the report.Suntory is seeking to diversify beyond alcoholic beverages as consumption trends shift, while Daiichi Sankyo is expected to focus resources on prescription drugs amid rising research and development costs, the report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

TYO:2587TYO:4568

Track with the FINWIRES app suite